Answers are grounded in this paper and cite their sources.
Amyloid positivity establishes the biological presence of Alzheimer’s disease (AD), but it does not fully capture downstream neuronal dysfunction. We hypothesized that routinely measured peripheral nutritional and metabolic biomarkers would be associated with AD-signature cerebral glucose hypometabolism in amyloid-positive AD. In this single-center observational study, 512 patients evaluated for cognitive impairment between January 2023 and October 2025 were screened, and 410 amyloid-positive AD patients with complete clinical assessment, amyloid PET, 18F-florbetapir PET (FDG-PET), and key laboratory data were included. The primary outcome was the continuous AD-signature FDG-PET metabolic Z score; secondary analyses classified 194 patients as having cerebral glucose hypometabolism and 216 as having relatively preserved metabolism using a prespecified Z-score threshold of −1.65. Compared with the preserved group, patients with hypometabolism were older, had longer disease duration, lower Chinese Mini-Mental State Examination and Montreal Cognitive Assessment scores, higher composite cortical 18F-florbetapir (AV45) standardized uptake value ratio, and lower regional FDG-PET Z scores across AD-vulnerable cortices. They also showed a distinct peripheral profile, with higher homocysteine, fasting glucose, glycated hemoglobin, triglycerides, cortisol, C-reactive protein, and erythrocyte sedimentation rate, and lower vitamin B12, folate, albumin, prealbumin, total protein, high-density lipoprotein cholesterol, apolipoprotein A1, and free triiodothyronine. Homocysteine showed the strongest negative correlation with AD-signature FDG-PET Z score ( r = −0.485), whereas albumin ( r = 0.466), prealbumin ( r = 0.427), free triiodothyronine ( r = 0.375), vitamin B12 ( r = 0.336), folate ( r = 0.308), and high-density lipoprotein cholesterol ( r = 0.262) were positively correlated. In fully adjusted models, these biomarkers remained independently associated with cerebral glucose metabolism. The clinical plus biomarker model achieved the highest discrimination for hypometabolism (area under the curve = 0.949; optimism-corrected area under the curve = 0.940). Peripheral nutritional and metabolic biomarkers may help identify amyloid-positive AD patients with greater downstream cerebral metabolic injury.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: